All Photos(1)

Documents

G2295

Glimepiride

Name: Glimepiride
Brand: SIGMA

≥98% (HPLC), solid

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₄H₃₄N₄O₅S

CAS Number:

93479-97-1

Molecular Weight:

490.62

MDL number:

MFCD00878417

UNSPSC Code:

12352200

PubChem Substance ID:

24895093

NACRES:

NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

solid

color

white

mp

212.2-214.5 °C

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

General description

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Application

Glimepiride has been used:

as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
as a sulfonylurea ATP-sensitive potassium channel (K_ATP) channel inhibitor in breast cancer MDA-MB-231 cells
in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac K_ATP channels activated by pinacidil with an IC₅₀ of 6.8 nM.

Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

GHS08

Signal Word

Warning

Hazard Statements

H361

Precautionary Statements

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.

Li-Ping Wang et al.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)

By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This

A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG

Tiwari A, et al.

International Journal of Advanced Research , 4, 920-927 (2016)

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

William T Cefalu et al.

Lancet (London, England), 382(9896), 941-950 (2013-07-16)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.

W Rathmann et al.

Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)

To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;

Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.

Mitsuyoshi Takahara et al.

Endocrine journal, 59(12), 1131-1136 (2012-08-02)

We retrospectively investigated the effect of adding dipeptidyl peptidase-4 (DPP-4) inhibitor and tapering sulfonylurea on blood glucose fluctuation in Asian patients with type 2 diabetes mellitus under basal-supported oral therapy (BOT). We recruited twenty-two consecutive Japanese patients with type 2

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service